Extended Data Fig. 8: Imaging mass cytometry (IMC) allows for single cell and spatial analysis.
a, Patient information (BMI and primary cancer type) for samples analyzed by IMC. Patients with an asterisk indicate those used for immunofluorescence validation. Patients with BMI<25.9 were assigned to the BMIlow group (ave BMI=24), and patients with a BMI>26 were assigned to the BMIhigh group (ave BMI=30; black line). b, IMC antibody panel information. c, Schematic of IMC staining workflow. Tissue sections were stained with antibody panel (as in b), and subject to CyTOF acquisition using a Hyperion imaging system. d, Immunofluorescence quantification of JAM1+ PyMT tumor cells in lung tissue from WT or ob/ob mice. WT, n = 10 mice; ob/ob, n = 8 mice; mean ± SEM; two-tailed Student’s t-test. e, Quantification of TEM of PyMT breast cancer cells infected with an shRNA against Jam1 (shJAM1) or scramble control (shSCR). n = 4 Transwells per group representing individual experimental replicates; mean ± SEM; two-tailed Student’s T test. f, Quantification of the average number of total CD163- CD68+ M1-like macrophages in BMIlow (n = 8 patients) and BMIhigh (n = 14 patients) lung metastasis samples. Box = median ± interquartile range, whiskers = min-max, all datapoints shown; two-tailed Mann–Whitney test.
